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Summary
 
Fas antigen (Apo-1/CD95) is an apoptosis-signaling cell surface receptor belonging to the tu-
mor necrosis factor receptor superfamily. Adult T cell leukemia (ATL) cells express Fas antigen
and show apoptosis after treatment with an anti-Fas monoclonal antibody. We established the
ATL cell line KOB, which showed resistance to Fas-mediated apoptosis, and found that KOB
expressed two forms of Fas mRNA, the normal form and a truncated form. The truncated
transcript lacked 20 base pairs at exon 9, resulting in a frame shift and the generation of a pre-
mature stop codon at amino acid 239. The same mutation was detected in primary ascitic cells
and peripheral blood cells. The mutation was not detected in lymph node cells, however, al-
though all of the primary ATL cells were of the same clonal origin. A retroviral-mediated gene
transfer of the truncated Fas to Jurkat cells rendered the cells resistant to Fas-mediated apop-
tosis, suggesting a dominant negative interference mechanism. These results indicate that an
ATL subclone acquires a Fas mutation in the lymph nodes, enabling the subclone to escape
from apoptosis mediated by the Fas/Fas ligand system and proliferate in the body. Mutation of
the Fas gene may be one of the mechanisms underlying the progression of ATL.
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T
 
he Fas antigen (Apo-1/CD95) is a 45-kD transmem-
brane protein that is a member of the TNF receptor
superfamily that can induce programmed cell death, i.e.,
apoptosis, when cross-linked by natural ligand or specific
antibodies. The human Fas antigen consists of 325 amino
acids with a single transmembrane domain, including signal
peptides. The extracellular domain is rich in cysteine resi-
dues and shows similarity to domains of human TNF recep-
tor, human nerve growth factor receptor, and human B cell
 
antigen CD40 (1). The cytoplasmic domain (
 
z
 
70 amino
acids), designated a death-signaling domain, is highly con-
served between Fas and TNF receptor and is necessary
for the transduction of the apoptotic signal. A deletion of
15 amino acids from the COOH terminus enhances the Fas
antibody–induced killing activity, whereas a further dele-
tion abolishes its activity (2). Fas can exist as both a cell sur-
face and a soluble protein, both of which are generated by
alternative splicing. While the cell surface Fas anchored by
a transmembrane domain induces apoptosis, soluble Fas pro-
tects cells from apoptosis (3–5).
The Fas/Fas ligand system of apoptosis appears to play an
important role in the normal development of T lympho-
cytes in the thymus by eliminating self-reactive lympho-
cytes (6, 7). Mutations in the Fas-encoding gene are respon-
 
sible for the lymphoproliferative disorder in 
 
lpr
 
 and 
 
lpr
 
cg
 
mice, which are models of autoimmune disease. These mice
fail to eliminate self-reactive T lymphocytes, resulting in the
accumulation of a large number of nonmalignant CD4
 
2
 
CD8
 
2
 
 T lymphocytes in the lymph nodes and spleen (8–
10). Similarly, several recent studies have identified function-
ablating mutations of the Fas antigen in patients with a
human lupus–like syndrome, designated congenital auto-
immune lymphoproliferative syndrome (ALPS),
 
1
 
 which is
identical to the 
 
lpr
 
 mouse phenotype and characterized by
lymphadenopathy, hypergammaglobulinemia, and autoimmu-
nity. Interestingly, such mutations of the Fas gene inhibited
the Fas-mediated apoptosis by a dominant negative mecha-
nism (11–14).
 
1
 
Abbreviations used in this paper:
 
 ALPS, autoimmune lymphoproliferative
syndrome; ATL, adult T cell leukemia; HTLV-I, human T lympho-
trophic virus type I; LDH, lactic dehydrogenase; nt, nucleotide; RT, re-
verse transcriptase. 
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Adult T cell leukemia (ATL) is a mature helper T cell–
derived lymphoma (15, 16) caused by human T lympho-
tropic virus type I (HTLV-I; 17–19). ATL is endemic to
the southwest area of Japan, the Caribbean Basin, West Af-
rica, and the southern United States. Because the clinical
features of ATL patients are quite diverse, ATL is usually
classified into four subtypes—acute, lymphoma, chronic,
and smoldering—according to the criteria of Shimoyama
(20). Compared with non-Hodgkin’s lymphoma patients,
ATL patients show significantly shorter terms of survival;
the median survival time is only 6.2 mo for an acute ATL
patient and 10.2 mo for patients with the lymphoma type
of ATL (21). The mechanism of chemoresistance of ATL
cells is not yet well understood. ATL cells express abundant
Fas antigen on their surfaces and undergo apoptosis induced
by an IgM anti-Fas mAb in vitro (22–25), but ATL cells do
not show apparent apoptosis in vivo.
Several Fas gene mutations have been reported in pri-
mary samples of myeloma, T cell lymphoblastic leukemia,
and ATL in patients other than our present patient (26–28),
which suggests that Fas resistance contributes to the devel-
opment of neoplasms. However, a functional analysis of the
detected mutant Fas gene in these diseases has not, to our
knowledge, been performed. In this study, we found that
the ATL cell line KOB carried a heterozygous Fas gene
mutation in exon 9 lacking a death-signaling domain and
acquired Fas resistance. The same mutation was detected in
the primary samples, ascites, and peripheral blood but not
in the lymph node. Moreover, by transfer of the mutant
Fas gene to Fas-sensitive Jurkat cells, we observed that the
aberrant Fas antigen functioned as a dominant negative in-
terfering Fas signal.
 
Materials and Methods
 
Patient.
 
A 72-yr-old man visited our hospital with com-
plaints of low grade fever and systemic lymphadenopathy in April
1992. His white blood cell count was 1.2 
 
3
 
 10
 
10
 
/liter, with 8%
abnormal lymphocytes. His lactic dehydrogenase (LDH) level and
serum calcium level were 4,400 IU/liter and 11 mg/dl, respec-
tively. The diagnosis of acute type ATL was made hematocyto-
logically and confirmed by the demonstration of monoclonal in-
tegration of HTLV-I proviral DNA in the peripheral blood and
lymph node mononuclear cells. The patient was administered 10
cycles of combination chemotherapy and discharged with a par-
tial response. However, only 3 mo after the discontinuation of
chemotherapy, the patient was readmitted to our hospital with
massive ascites and an elevated LDH level (4312 IU/liter). Al-
though combination chemotherapy was started again, the effect
was transient and the patient died of a systemic invasion of ATL
cells 3 mo after his second hospital admission.
 
Clinical Samples and Cell Lines.
 
Peripheral blood was drawn
several times during the patient’s hospital stays. A lymph node
was biopsied during his first admission, and ascites were obtained
during his second admission. All materials were obtained after in-
formed consent. Mononuclear cells were separated from the sam-
ples by centrifugation over a Ficoll gradient and cryopreserved
until use. The ATL cell line KOB was established from the pa-
tient’s ascitic ATL cells. The other three ATL cell lines (KK1,
ST1, and SO4) used for the present study were also of primary
ATL cell origin established from the respective ATL patients (29,
30). All ATL cell lines were dependent on exogenously added IL-2
and were maintained in RPMI 1640 supplemented with 10% FBS
and 0.5 U/ml IL-2.
 
Flow Cytometric Analysis for Membrane Fas.
 
Membrane Fas was
examined by flow cytometry as described previously using a Cytron
flow cytometer (Ortho; 31). The resulting histograms (see Fig. 1)
correspond to the cell number (y-axis) versus fluorescence inten-
sity (x-axis) plotted on a logarithmic scale.
 
RNA Extraction and Reverse Transcriptase (RT)-PCR.
 
Total
RNA was prepared from the cell lines and clinical samples using
ISOGEN (Wako). After the removal of DNA contamination us-
ing a MassageClean™ kit (GenHunter Corp.), cDNA was made
from 1 
 
m
 
g of total RNA using an RNA PCR core kit (Perkin
Elmer) according to the manufacturer’s protocol. Oligo dT prim-
ers were used to prime the first strand synthesis for each of the re-
actions. Four oligonucleotide primer pairs were designed to am-
plify the full length coding region of Fas according to the method
of Cheng et al. (3). The reaction conditions were 35 cycles of
94
 
8
 
C for 70 s, 60
 
8
 
C for 30 s, and 72
 
8
 
C for 60 s (for full length
Fas) or 30 cycles of 95
 
8
 
C for 60 s, 54
 
8
 
C for 60 s, and 72
 
8
 
C for 60 s
(for Fas I, Fas II, and Fas III; Table I). These amplified products
were electrophoretically separated and visualized on an ethidium
bromide–stained 2% agarose gel or a silver-stained 12.5% acryla-
mide gel using a GenePhor electrophoresis unit (Pharmacia Bio-
tech).
 
Subcloning and Sequencing.
 
We cloned the RT-PCR products
of full length Fas and Fas III derived from KOB or clinical sam-
ples into the pCR™II vector using a TA cloning kit (Invitrogen
Corp.). All sequencing experiments were performed using an
AutoRead™ sequencing kit designed for an ALF™ DNA se-
quencer (Pharmacia Biotech).
 
Construction of Retroviral Vectors and Transfection.
 
The truncated
full length Fas cDNA of KOB origin was inserted into the retro-
viral vector LXSN. This vector contains Moloney murine sar-
coma virus–derived long terminal repeats and a neomycin resis-
tance gene under the control of simian virus 40 early promoter.
The recombinant retroviral vector LdelSN was purified using an
EndoFree Plasmid Maxiprep kit (Qiagen) and was transfected
into the ecotropic packaging cell line 
 
c
 
2 using FuGENE™6
transfection reagent (Boehringer Mannheim). After a 48-h culture
in DMEM, the transient retroviral supernatant was used to trans-
duce the amphotropic packaging cell line PA317. The PA317
cells infected with recombinant retroviruses were cultured in
DMEM for 48 h and selected with 0.8 mg/ml G-418. Superna-
tants of PA317 cells producing amphotropic retroviruses were
used to transduce Jurkat cells. The transduced Jurkat cells were se-
lected in RPMI 1640 containing 1 mg/ml G-418 and were cloned
by the colony formation method on methylcellulose-containing
culture plates.
 
Detection of HTLV-I Proviral DNA and TCR Gene Rearrange-
ment Profile.
 
The integration site(s) of HTLV-I proviral DNA
and TCR gene rearrangement were examined with a Southern
blot hybridization assay using probes for the pX region of
HTLV-I and TCR C
 
b
 
1 according to the described method (24,
32). In brief, the high molecular DNA samples (10 
 
m
 
g) extracted
from the cell lines and clinical samples were digested with restric-
tion enzymes and size fractionated on 0.7% agarose gels. They
were then denatured and transferred onto positively charged ni-
trocellulose membranes (Boehringer Mannheim) and hybridized
to digoxigenin-labeled probes. Thereafter, the blots were washed
at appropriate stringency and treated with an anti-digoxigenin 
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antibody conjugated with alkaline phosphatase (Boehringer Mann-
heim), and the alkaline phosphatase was changed to a light signal
by CDP-Star™ (Boehringer Mannheim) and exposed to film.
The restriction enzymes used were EcoRI and PstI for HTLV-I
proviral DNA and EcoRV and BamHI for TCR 
 
b
 
 chain gene
rearrangement.
 
Detection of Apoptosis.
 
In the process of early apoptosis, cells
express phosphatidylserine on the outer leaflet of the cell surface
membrane and consequently bind annexin V. Cell lines cultured
with or without IgM anti-Fas mAb at a final concentration of
1 
 
m
 
g/ml were examined for annexin V binding by flow cytome-
try at several time points after culture using an annexin V–FITC
kit (Takara Shuzo Co.) according to the manufacturer’s protocol.
A DNA fragmentation analysis was also performed using the same
samples and an apoptosis ladder detection kit (Wako).
 
Cell Proliferation Assay.
 
First, 10
 
5
 
 cells/100 
 
m
 
l RPMI 1640
supplemented with 10% FCS were cultured with or without
1 
 
m
 
g/ml of IgM anti-Fas mAb in 96-well tissue culture plates for 7,
16, 24, or 32 h, and proliferation status was estimated by measuring
the conversion of MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy-
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) into
water-soluble formazan (CellTiter 96TMAQueous; Promega)
according to the manufacturer’s protocol. All experiments were
performed in triplicate.
 
Results
 
Expression of Fas Antigen on Cell Lines and Response to IgM
anti-Fas mAb.
 
Four ATL cell lines were analyzed for the
expression of Fas antigen (Apo-1/CD95) by flow cytome-
try using an IgG anti-Fas mAb. As shown in Fig. 1, all four
ATL cell lines (KK1, KOB, ST1, and SO4) and Jurkat cells
expressed Fas antigen, whereas the cell line K562 used as a
negative control did not. These cell lines were cultured
with 1 
 
m
 
g/ml IgM anti-Fas mAb, and cell proliferation status
was examined. The results are expressed as a value against
the control cells cultured without mAb. As shown in Fig.
2 A, after a 24-h culture with the mAb, the proliferation of
KK1, SO4, and ST1 cells was significantly suppressed: to
16.8, 7.7, and 10.8% of the control level, respectively. In
contrast, the KOB and K562 cells were not affected. To
confirm that suppression was due to apoptosis, we per-
formed a flow cytometric analysis of annexin V binding and
a DNA fragmentation assay for the early and late phases of
apoptosis, respectively. In Jurkat cells, an annexin V–binding
cell population appeared 3 h after treatment with IgM anti-
Fas mAb (14%), and the population was further increased
at 5 h (50.1%). In contrast, no annexin V–binding cell pop-
ulation appeared in KOB cells (Fig. 2 B). Likewise, the
other ATL cell lines (KK1, SO4, and ST1) exhibited an-
nexin V binding but K562 cells did not (data not shown).
Supporting the results of annexin V binding, DNA ladder
formation appeared in the three ATL cell lines (KK1, SO4,
and ST1) but not in KOB and K562 cells after 3 h of cul-
ture (data not shown). These results prompted us to exam-
ine the mechanism of Fas resistance in KOB cells.
 
RT-PCR and Sequencing of Fas Gene.
 
To investigate the
Fas mRNA, four primer pairs were designed to cover its full
length coding region. These PCR reactions were named
Fas I, Fas II, and Fas III (Table I). The expected size of the
bands in Fas I and Fas III was 336 and 344 bp, respectively.
Fas II was expected to show two bands (339 and 276 bp)
generated by alternative splicing; the larger PCR product
corresponds to the membrane form, and the smaller prod-
uct corresponds to the soluble form of Fas mRNA, which
 
Table I.
 
Fas Primers
 
Gene segment Primer sequence PCR product
Fas full length Sense:  5
 
9
 
-CACTTCGGAGGATTGCTCAACA
Antisense: 5
 
9
 
-TATGTTGGCTCTTCAGCGCTA 1,167 bp (nt. 170–1336)
Fas I Sense:  5
 
9
 
-ATGCTGGGCATCTGGACCCT
Antisense: 5
 
9
 
-GCCATGTCCTTCATCACACAA 336 bp (nt. 195–530)
Fas II Sense:  5
 
9
 
-CATGGCTTAGAAGTGGAAAT
Antisense: 5
 
9
 
-ATTTATTGCCACTGTTTCAGG 339 bp (nt. 525–863)
Fas III Sense:  5
 
9
 
-AAATTTATCTGATGTTGACT
Antisense: 5
 
9
 
-TCTAGACCAAGCTTTGGATTTC 344 bp (nt. 860–1203)
cDNA nucleotide numbers correspond to those reported by Itoh et al. (1).
Figure 1. Flow cytometric analysis of Fas antigen. All cell lines but one
(K562) expressed the Fas antigen on their surfaces. Cells were incubated
with IgG anti-Fas mAb (solid line) or control mAb (dashed line). 
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is 63 bp shorter than the membrane form. Irregardless of
the samples, only the expected bands were observed in the
Fas I and Fas II reactions. In contrast, in the Fas III reaction
of KOB cells, a distinct  smaller product was observed in
addition to the expected 344-bp band (Fig. 3 A). The se-
quencing analysis of full length RT-PCR products of KOB
cells showed two transcripts, the normal form and a trun-
cated form. The truncated transcript lacked 20 bp (from nu-
cleotide [nt] 686 to nt 705, nucleotide numbers that corre-
spond to those reported by Itoh et al. [1]) at exon 9 within
the cytoplasmic death-signaling domain. The frame shift
caused by the deletion generated a premature stop codon at
amino acid 239, resulting in the production of aberrant Fas
antigen which lacked the entire death-signaling domain
(Fig. 3 B).
 
Origin of KOB Cell Line.
 
Hematocytologically, charac-
teristic ATL cells with deeply indented or lobulated nuclei
and relatively scanty basophilic cytoplasm were observed in
the peripheral blood, lymph node, and ascites of our pa-
tient. We examined the integration pattern of HTLV-I
Figure 2. Response to IgM anti-Fas mAb. (A) Proliferation status after treatment with IgM anti-Fas mAb. Results are expressed as values against the
control cells cultured without mAb. The proliferation of three ATL cell lines, SO4 (open circle), KK1 (filled circle), and ST1 (filled triangles) were
strongly suppressed to 7.7, 16.8, and 10.8% of the control level, respectively, whereas KOB (open square) and K562 (filled square) cells were not affected.
Data are the mean 6 SD from three independent experiments. (B) Flow cytometric detection of annexin V binding. Jurkat cells clearly exhibited an-
nexin V binding 3 h after treatment with IgM anti-Fas mAb (14%), and the binding population was further increased at 5 h (50.1%), whereas no annexin
V binding was observed in KOB cells.
Figure 3. Detection of Fas gene mutation. (A) RT-PCR analysis of human Fas mRNA. The expected bands for Fas I and Fas III were 336 and 344
bp, respectively. Due to alternative splicing, two expected bands (339 bp and 276 bp) were detected in Fas II analysis. No difference in Fas I and Fas II
was observed between samples. For Fas III, in addition to the expected 344-bp band, a distinct smaller product was observed in lane 4, which corresponds
to KOB cells. Lanes 1–4 correspond to the ATL cell lines SO4, ST1, KK1, and KOB, respectively. Lanes 5 and 6 correspond to freshly isolated ATL
cells. Lane 7 is a normal control. (B) Sequencing analysis of RT-PCR products of KOB cells. The aberrant transcript that lacks 20 bp (from nucleotide
686 to nucleotide 705, numbers that correspond to those reported by Itoh et al. [1]) at exon 9 was detected. The frame shift caused by this deletion gen-
erates a premature stop codon at amino acid 239. 
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proviral DNA and TCR 
 
b
 
 chain gene rearrangement pro-
files by Southern blot analysis to determine the origin of
KOB cells. As shown in Fig. 4 A, one monoclonal band
was observed at the same position in all primary samples
when cellular DNAs was digested with EcoRI or PstI. In
addition, multiple bands other than the original band of the
primary samples were observed in KOB cells, suggesting
the superinfection of HTLV-I in vitro. In the TCR 
 
b
 
chain gene rearrangement profile, the same rearranged band
(Fig. 4 B, arrowhead R) was observed in all samples includ-
ing KOB when the cellular DNA was digested with BamHI.
The loss of the germline band at 12 kb was observed in all
but one sample (peripheral blood) when the cellular DNA
was digested with EcoRV, indicating the deletion of the
TCR C
 
b
 
 1 locus in this clone (Fig. 4 B). The germline band
at 12 kb observed in peripheral blood indicates the presence
of normal non-T cells. These results suggest that KOB cells
originated from the primary ATL cells. We therefore investi-
gated whether the primary samples also expressed the trun-
cated Fas gene. We performed an RT-PCR analysis of Fas
III in all primary samples. Interestingly, although the same
smaller product observed in KOB cells was detected in pe-
ripheral blood ATL cells and ascitic ATL cells, no such prod-
uct was detected in lymph node ATL cells (Fig. 4 C). The
sequence analysis of these products disclosed that the clinical
samples from peripheral blood and ascites had the same Fas
gene mutation observed in KOB cells. No such mutation
was observed in the lymph node cells (data not shown).
 
Retroviral-mediated Transfer of the Mutant Fas Gene.
 
To
confirm that the mutant Fas gene is responsible for Fas re-
Figure 4. Origin of KOB cells. (A) Southern blot analysis of HTLV-I proviral DNA. A monoclonal band is observed at the same position in all pri-
mary samples. Multiple extra bands are observed in lanes 4 and 8, which correspond to KOB cells, suggesting the superinfection of HTLV-I in vitro. Lanes
1 and 5, peripheral blood ATL cells; lanes 2 and 6, lymph node ATL cells; lanes 3 and 7, ascitic ATL cells; lanes 4 and 8, KOB cells; M, size marker. (B)
TCR Cb gene rearrangement profile. The same rearranged bands (arrowhead R) were observed in all samples digested with BamHI. With EcoRV di-
gestion, the loss of the germline band at 12 kb is observed in lanes 8–10. The germline band at 12 kb in lane 8 indicates the presence of some non-T cells
in the peripheral blood. Lanes 1 and 7, human placenta; lanes 2 and 8, peripheral blood ATL cells; lanes 3 and 9, lymph node ATL cells; lanes 4 and 10,
ascitic ATL cells; lanes 5, 6, 11, and 12, KOB cells; G, germline bands. (C) RT-PCR analysis of Fas III reaction. In addition to the normal 344-bp band
(arrow 1), the same distinct smaller products (arrow 2) are observed in lanes 2, 4, and 5. Lane 1, Jurkat cells; lane 2, KOB cells; lane 3, lymph node ATL
cells; lane 4, peripheral blood ATL cells; lane 5, ascitic ATL cells; lane 6, peripheral blood mononuclear cells from a healthy volunteer. M, size marker.
Figure 5. Retroviral-mediated gene transfer and response to IgM anti-Fas mAb. (A)
RT-PCR analysis in Fas III reaction. All LdelSN-transduced Jurkat cell clones (lane 5, RJ-9;
lane 6, RJ-11; lane 7, RJ-14) expressed two transcripts corresponding to the normal Fas
(arrow 1) and truncated Fas (arrow 2), but only the normal transcript was detected in wild-type (lane 1) and all LXSN-transduced Jurkat cell clones (lane
2, LX-1; lane 3, LX-2; lane 4, LX-3); M, size marker. (B) Flow cytometric detection of annexin V binding. A marked increase in the annexin V–binding
cell population was observed in the LXSN-transduced Jurkat cell clone LX-2 after a 3-h culture with mAb (3.3% at 0 h, 3.1% at 1 h, 56.8% at 3 h, and
77.2% at 5 h). No increase was detected in the LdelSN-transduced Jurkat cell clone RJ-14. (C) Evaluation of proliferation status. The proliferation of
LXSN-transduced Jurkat cell clones LX-1 (filled square) and LX-3 (filled circle) was significantly suppressed to 37.6 and 33.4% of the control level, re-
spectively, but the LdelSN-transduced Jurkat cell clones RJ-9 (open circle), RJ-11 (open triangle), and RJ-14 (open square) were not affected by mAb.
Data are the mean 6 SD from three independent experiments. 
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Figure 6. Morphological changes after treatment with mAb. May-Grünwald Giemsa staining at an original magnification of 1000 is shown. The char-
acteristic features of apoptosis, including the reduction of cell size, condensation and aggregation of nuclear chromatin, and nuclear fractionation, were
observed in wild-type Jurkat cells and LXSN-transduced Jurkat cell clones; no morphological change was observed in the LdelSN-transduced Jurkat cell
clone.
 
sistance in KOB cells, we constructed the retroviral vector
LdelSN containing the truncated Fas cDNA and transferred
it into Jurkat cells. The successful transfer of the gene in
G418-resistant cells was confirmed by RT-PCR of Fas III
and neomycin resistance gene–specific sequences and by
sequencing analysis. RT-PCR analysis of Fas III showed
two transcripts in all LdelSN-transduced Jurkat cell clones
(RJ-9, RJ-11, and RJ-14) but only normal transcript in
wild-type and LXSN-transduced Jurkat cell clones (LX-1,
LX-2, and LX-3; Fig. 5 A). We performed a sequencing
analysis of the RT-PCR products from transduced Jurkat
cells and verified the expression of transferred Fas gene
(data not shown).
The LXSN- and LdelSN-transduced Jurkat cells were
assayed for Fas sensitivity. The flow cytometric analysis of
annexin V binding showed that the LXSN-transduced Jur-
kat cell clone LX-2 demonstrated a marked increase of the
annexin V–binding cell population of 3.3% at 0 h to 56.8%
at 3 h after treatment with IgM anti-Fas mAb, and the pop-
ulation increased further to 77.2% at 5 h. In contrast, the
LdelSN-transduced Jurkat cell clone RJ-14 showed no such
increase (Fig. 5 B). Using CellTiter 96TMAQueous, the pro-
liferation status was evaluated at several time points of cul-
ture with 1 
 
m
 
g/ml of IgM anti-Fas mAb. The proliferation
of the LXSN-transduced Jurkat cell clones LX-1 and LX-3
was significantly suppressed to 37.6 and 33.4% of the con-
trol level, respectively, but the LdelSN-transduced Jurkat
cell clones RJ-9, RJ-11, and RJ-14 were not affected (Fig.
5 C). The characteristic features of apoptosis, i.e., reduction
of cell size, condensation and aggregation of nuclear chro-
matin, and nuclear fractionation were observed in wild-type
Jurkat cells and LXSN-transduced Jurkat cell clones but not
in LdelSN-transduced Jurkat cell clones (Fig. 6).
 
Discussion
 
Most ATL cells express abundant Fas antigen on their
surfaces and show apoptosis in a short term culture with
IgM anti-Fas mAb (22, 23, 25, 33). We reported that ATL
cells from all but 2 of 33 patients expressed Fas antigen, and
the Fas
 
2
 
 ATL cells were resistant to apoptosis (34). Differ-
ences in Fas expression seem to be correlated with subtypes
of ATL; the level of Fas expression was higher in chronic
type than in acute type ATL patients and was inversely cor-
related with serum LDH activity (24, 25). These results
may indicate that the Fas/Fas ligand system plays a critical
role in elimination of ATL cells.
Fas gene mutations were recently reported in some malig-
nancies. 7 cases of malignancy with Fas gene mutations were
detected in 48 multiple myeloma patients by the RT-PCR
method and a single-stranded conformation polymorphism
(SSCP) analysis. All of these mutations were point mu-
tations in the cytoplasmic region, and two of them were
silent mutations (26). 2 cases of Fas gene mutations were 
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found among 81 childhood T-lineage acute lymphoblastic
leukemia patients using PCR and single-stranded confor-
mation polymorphism analysis as the screening methods;
one case was a heterozygous point mutation in exon 3, and
another case was a homozygous alteration in the promoter
region (27). The 3 cases of Fas gene mutations detected
among 47 ATL patients by an RNase protection assay were
a 5-bp deletion in exon 2, a 1-bp insertion in exon 2, and a
loss of exon 4. Two silent point mutations were also ob-
served (28). Rearrangement or allelic loss of Fas gene were
also reported in 5 of 70 patients with non-Hodgkin’s lym-
phoma: 3 cases of allelic loss and 2 cases of rearrangement
(35). According to these reports, it is likely that Fas gene
mutations, including silent mutations, occur at relatively
low but diverse frequencies, 
 
z
 
2.5–14.6%, and are consis-
tently detected in lymphoid malignancies, suggesting an as-
sociation between Fas mutation and disease progression in
lymphoid malignancies. However, a functional analysis of
the aberrant Fas was not performed in any of the above
studies.
In many receptor and ligand systems such as epidermal
growth factor, fibroblast growth factor, and platelet-derived
growth factor 
 
b
 
, dimerizations of receptor subunits appear
to be essential for signal transduction. The truncated forms
of these receptors suppress the response of wild-type recep-
tor by heterodimerization (36–41). Analysis of the crystal
structure of TNF receptor–TNF-
 
b
 
 complex demonstrated
that three TNF receptor molecules symmetrically bound to
TNF-
 
b
 
 trimer (42). The human soluble Fas ligand also
forms homotrimers (43). It has been reported that the tri-
merization of the death-signaling domain within the cyto-
plasmic region of Fas is essential for signal transduction in
the process of Fas-mediated apoptosis (44). Therefore, it is
likely that KOB cells prevented apoptosis by an expression
of function-ablating Fas antigen on their surfaces similar to
the expression on lymphocytes of ALPS patients. The trun-
cated Fas antigen, which lacks the entire death-signaling
domain, may behave as a decoy receptor and interfere with
the trimerization of normal Fas in a competitive manner,
resulting in the impairment of signal transduction.
To test this hypothesis, we constructed the retroviral
vector LdelSN containing the truncated Fas cDNA and
transferred it into Jurkat cells, which are sensitive to IgM
anti-Fas mAb. The resulting Jurkat cells became almost
completely resistant to IgM anti-Fas mAb, suggesting that
heterotrimers between the truncated Fas and normal Fas,
which was endogenously expressed in Jurkat cells, did not
transduce the apoptotic signal. Although the pathological
role of aberrant Fas antigen has been demonstrated in ALPS
by the method of transient gene transfer, no such trial has
been performed in neoplasms. The present study is, to our
knowledge, the first that has successfully demonstrated the
dominant negative inhibition of apoptosis by a stably trans-
fected cell line.
More interestingly, the mutated Fas gene observed in
KOB cells was not detected in lymph node ATL cells, al-
though a Southern blot analysis indicated that all of the pri-
mary ATL cells and KOB cells were of the same cell origin.
These results indicate that ATL cells developed in the
lymph nodes have acquired Fas gene mutation, and the
subclone with the mutation spread to the whole body, es-
caping elimination by the Fas/Fas ligand system. It has been
suspected that HTLV-I–infected T lymphocytes proliferate
in lymph nodes at an early phase of malignant alteration
and gradually progress from the carrier type to the smolder-
ing, chronic, and acute types of ATL. Based on a statistical
analysis of the age distribution of ATL patients, the lym-
phomagenesis of ATL was proposed to consist of at least
five steps (45). Although abnormalities in tumor suppressor
genes such as p53, p15, or p16 are supposed to be one of
the steps for progression of ATL (46–48), the precise mech-
anism of lymphomagenesis remains unknown. Function-
ablating Fas mutations might be involved in the multistep
lymphomagenesis of ATL.
It is, however, unlikely that the Fas gene mutation alone
leads to a malignant transformation. Fas-deficient lpr mice
do not develop malignancies, and patients with ALPS have
rarely developed malignancies. Interestingly, lpr mice,
which constitutively express the L-myc transgene in the
lymphoid lineage, show an accelerated formation of T and
B cell lymphomas, but the L-myc transgene alone did not
produce such an acceleration in normal mice (49). It has
been reported that mice deficient in both T cells and Fas
gene develop B cell lymphoma (50). These reports suggest
that lymphomagenesis requires other events besides the loss
of Fas receptor function. In the present investigation, it
seems feasible that lymph node ATL cells with some ge-
netic abnormalities that are crucial for the development of
ATL progressed to a more aggressive form by acquiring a
Fas gene mutation.
In conclusion, we found a function-ablating Fas gene
mutation in an ATL cell line (KOB) and its primary ATL
cells. By retrovirus-mediated gene transfer, we verified that
the aberrant Fas interfered with apoptosis by a dominant
negative mechanism. The absence of the Fas gene mutation
in lymph node ATL cells suggests that this mutation is a
late event that occurs after the development of ATL and
that the ATL subclone with Fas mutation escaped from the
apoptosis mediated by the Fas/Fas ligand system and spread
to the entire body of the patient. Abnormality of Fas func-
tion may be one of the important steps in the progression
of ATL.
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